azd8233
Nucleic acidexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 3, 2018 (NCT03593785)
Timeline
Indications
Mechanism of action
- Subtilisin/kexin type 9ANTISENSE INHIBITOR
PCSK9 antisense inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05065463 | Phase 1 | Nov 7, 2021 | AstraZeneca, Parexel |
| NCT04964557 | Phase 2 | Jul 7, 2021 | AstraZeneca |
| NCT04823611 | Phase 1/Phase 2 (Phase 2) | Jan 20, 2021 | AstraZeneca |
| NCT04641299 | Phase 2 | Oct 28, 2020 | AstraZeneca |
| NCT04155645 | Phase 1 | Nov 21, 2019 | AstraZeneca, Parexel |
| NCT03593785 | Phase 1 | Aug 3, 2018 | AstraZeneca, Parexel |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 6 | 6 | 2 | 2018 |
| Parexel | For profit | 3 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1